Reversing Liver Disease? Scientists Discover New Health Benefit of Semaglutide

Reversing Liver Disease? Scientists Discover New Health Benefit of Semaglutide

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New England Journal of Medicine reveals that semaglutide significantly improves outcomes for patients with a serious form of liver disease, benefiting approximately two-thirds of those treated. The findings come from the ESSENCE phase 3 clinical trial, a [...]

GSK pays $1.2bn for liver drug as it culls TIGIT programme

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH

GSK to buy liver disease drug for $1.2B

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.

GSK to buy experimental MASH drug for $1.2B upfront

The deal for Boston Pharmaceuticals' efimosfermin will help the U.K. drugmaker shore up its pipeline of future medicines.

GSK to Buy Liver Disease Drug For as Much as $2 Billion

GSK Plc agreed to buy an experimental medicine to treat liver disease for as much as $2 billion as the UK drugmaker seeks to shore up its pipeline of new medicines.

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

GSK will hand over $1.2 billion in upfront cash to license a closely-watched candidate for fatty liver disease from Boston Pharmaceuticals. The drug in question is Boston Pharma’s lead asset, efimosfermin alfa. Previously known as ...